Product Description
Mechanisms of Action: Imaging Agent Imaging Agent
Novel Mechanism: Yes
Modality: Diagnostic Agent
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EORTC
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| EORTC-10003-16004 | P2 |
Completed |
Breast Cancer |
2002-06-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|